Prostaglandin Market Size Driven by Expanding Therapeutic Applications in Cardiovascular and Gynecological Treatments | Valuates Reports

Prostaglandin- Market Size
The global market for Prostaglandin was estimated to be worth US$ 554 million in 2024 and is forecast to a readjusted size of US$ 889 million by 2031 with a CAGR of 7.1% during the forecast period 2025-2031.

View sample report
https://reports.valuates.com/request/sample/QYRE-Auto-14K6903/Global_Prostaglandin_Market_Insights_and_Forecast_to_2028

The global Prostaglandin Market is witnessing strong growth, fueled by its widening use across cardiovascular, gynecological, obstetrical, and ophthalmologic applications. Increasing adoption in precision medicine, drug development, and hormone-related therapies continues to drive demand for both human and veterinary prostaglandins.

Among types, the human prostaglandin segment dominates market share due to its critical role in cardiovascular regulation, reproductive health, and glaucoma treatment. Rising incidences of cardiovascular disorders and obstetric complications are expanding the use of synthetic and semi-synthetic prostaglandins in medical formulations. Meanwhile, the veterinary prostaglandin segment is gaining traction, driven by the growing animal healthcare market and the need for effective reproductive management in livestock and companion animals.

By application, gynecological and obstetrical uses represent a major growth area, supported by the rising use of prostaglandins in labor induction, pregnancy termination, and postpartum hemorrhage management. The ophthalmologic segment is also expanding rapidly, primarily due to the increasing prevalence of glaucoma and ocular hypertension, where prostaglandin analogs are among the most effective first-line therapies.

Key players in the Prostaglandin Market include Sanofi CEPiA, Kyowa Hakko Pharma, Cayman Chemical, Johnson Matthey, Chirogate, and Everlight Chemical, which lead the market through strong product portfolios and manufacturing capabilities. Emerging companies such as Yonsung Fine Chemicals, ANVI Pharma, AUSUN Pharmaceutical, and Aspen Biopharma Labs are investing in research and development to strengthen their market presence and supply chains.

Regionally, North America and Europe maintain strong market dominance owing to advanced pharmaceutical manufacturing infrastructure, well-established regulatory frameworks, and growing therapeutic innovation. Asia-Pacific is expected to witness the fastest growth, led by countries such as China, Japan, South Korea, and India, where pharmaceutical R&D investment and biosynthetic prostaglandin production are rising rapidly. Meanwhile, Latin America and the Middle East & Africa are emerging markets driven by increasing access to healthcare and expanding pharmaceutical distribution networks.

Overall, the Prostaglandin Market is set for substantial expansion as innovations in biosynthesis, drug delivery, and therapeutic formulations continue to shape next-generation cardiovascular, reproductive, and ophthalmologic treatments.

Segment by Type

• Human Prostaglandin
• Veterinary Prostaglandin

Segment by Application

• Cardiovascular
• Gynecological and Obstetrical
• Ophthalmologic
• Other

By Company

Sanofi CEPiA, Kyowa Hakko Pharma, Cayman Chemical, Yonsung Fine Chemicals, Johnson Matthey, Chirogate, Everlight Chemical, ANVI Pharma, AUSUN Pharmaceutical, Aspen Biopharma Labs

View full report
https://reports.valuates.com/market-reports/QYRE-Auto-14K6903/global-prostaglandin

Valuates,
4th Floor,
Balaraj's Arcade,
Whitefield Main road,
Bangalore 560066,

Valuates offers an extensive collection of market research reports that helps companies to take intelligent strategical decisions based on current and forecasted Market trends.

This release was published on openPR.